Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Colorectal Cancer

What Is the Best Way to Screen for Colorectal Cancer?
With the availability of stool-based and at-home tests, is traditional colonoscopy still necessary? Read More ›

Drugs for Colorectal Cancer
Find financial assistance programs available for colorectal cancer drugs. Read More ›

No Evidence of Disease, or NED: How Is It Going for You?
Joe Bullock finally heard the 3 little letters he’d been waiting to hear since his colorectal cancer diagnosis: NED. But he wasn’t expecting the uncertainty that shortly followed, feeling stuck in the in-between phase “after cancer.” Read More ›

My Colon Cancer Journey: Finding New Passion in Survivorship
After ignoring his abdominal pain and blood in his stool because of family stresses, Joe Bullock finally had a colonoscopy done at the urging of his wife. A stage III colon cancer diagnosis and the support he received from other patients provided new insights. Read More ›

A Learning Experience
Losing weight and her appetite made Lydia Virgo go to the doctor to get a blood test, which showed a low iron count. Although exhibiting no pain, Lydia’s CT scan and colonoscopy revealed a tumor in her colon. Read More ›

What It Really Means to “Man Up”
Six months before he was diagnosed with stage IIIB colorectal cancer, both of Joe Bullock’s parents passed away. Chemotherapy hit him hard and stirred a mixture of depression and feelings of inadequacy as a husband and father. Then he discovered the power of opening up. Read More ›

My Metamorphosis Through Stage IV Colon Cancer
Crystal Ortner, PsyD, chronicles her difficult experiences with advanced-stage colon cancer and offers a heartfelt affirmation on the power of love. Read More ›

First-Line Treatment with Keytruda Doubles the Time without Disease Progression in Patients with MSI-H or dMMR Metastatic Colorectal Cancer
New study results presented at the 2020 ASCO annual meeting suggest that there is a new standard of care for the first-line treatment of some patients with advanced colorectal cancer. This was the first study to compare the use of Keytruda (pembrolizumab), a PD-1 inhibitor, versus chemotherapy to see which is the best first treatment for patients with metastatic (spreading) colorectal cancer and microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) abnormalities. Read More ›

Opdivo plus Yervoy May Be New First-Line Option for Patients with MSI-H or dMMR Colorectal Cancer
The use of first-line immunotherapy combination with Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) continues to show robust, long-term benefit in patients with microsatellite instability high (MSI-H) or with mismatch repair-deficient (dMMR) metastatic (spreading) colorectal cancer, according to new study results presented at the 2020 ASCO annual meeting. Read More ›

First-Line Immunotherapy New Standard of Care in Some Patients with Metastatic Colorectal Cancer
A new study was presented at the 2020 ASCO meeting that compared, for the first time, the use of immunotherapy versus chemotherapy for treating patients with metastatic colorectal cancer and microsatellite instability-high or mismatch repair-deficient abnormalities. Read More ›

Page 1 of 3